CAS: 945614-12-0 - Pexmetinib
- Synonyms:
- Arry-614
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Pexmetinib REF: IN-DA01E5Z7CAS: 945614-12-0 | 98% | To inquire | Wed 04 Dec 24 |
 | Pexmetinib REF: TM-T6934CAS: 945614-12-0 | 98.41% - 99.66% | 58.00 €~558.00 € | Wed 11 Dec 24 |
 | Pexmetinib REF: TR-P293620CAS: 945614-12-0 | - - - | 236.00 €~1,453.00 € | Tue 14 Jan 25 |
 | Pexmetinib REF: 3D-FP103620CAS: 945614-12-0 | Min. 95% | To inquire | Wed 15 Jan 25 |
Pexmetinib
CAS:945614-12-0
Formula:
C31H33FN6O3
Purity:
98%
Color and Shape:
Solid
Molecular weight:
556.6305
Ref: IN-DA01E5Z7
| 25mg | 175.00 € | ||
| 50mg | 293.00 € | ||
| 100mg | 468.00 € |
Estimated delivery in United States, on Wednesday 4 Dec 2024
Pexmetinib
CAS:945614-12-0
Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK/Tie-2 inhibitor.Cost-effective and quality-assured.
Formula:
C31H33FN6O3
Purity:
98.41% - 99.66%
Color and Shape:
Solid
Molecular weight:
556.63
- Inhibitors
- p38 MAPK
- Tyrosine Kinase/Adaptors
- Tie-2
- See more categories
- Autophagy
Ref: TM-T6934
| 2mg | 58.00 € | ||
| 5mg | 95.00 € | ||
| 10mg | 151.00 € | ||
| 25mg | 296.00 € | ||
| 50mg | 501.00 € | ||
| 100mg | 558.00 € | ||
| 1mL*10mM (DMSO) | 119.00 € |
Estimated delivery in United States, on Wednesday 11 Dec 2024
Pexmetinib
Controlled ProductCAS:945614-12-0
Applications Pexmetinib is a potent and orally bioavailable dual p38 MAPK/Tie-2 inhibitor preventing tumor growth. …
Formula:
C31H33FN6O3
Color and Shape:
Neat
Molecular weight:
556.63
Ref: TR-P293620
| 5mg | 236.00 € | ||
| 25mg | 691.00 € | ||
| 100mg | 1,453.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
Pexmetinib
CAS:945614-12-0
Pexmetinib is a tyrosine kinase inhibitor that binds to the ATP-binding pocket of the target …
Formula:
C31H33FN6O3
Purity:
Min. 95%
Molecular weight:
556.63 g/mol
Ref: 3D-FP103620
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire |
Estimated delivery in United States, on Wednesday 15 Jan 2025
